<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1010246028
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CISPLATIN 1MG-1ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CISPLATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        concentrate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        72.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA AUSTRALIA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA AUSTRALIA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA UK LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cisplatin forms part of a group of medicines called cytostatics, which are used in the treatment of cancer. Cisplatin can be used alone but more commonly Cisplatin is used in combination with other cyostatics.</p><p>&nbsp;</p><p><strong>What it is used for</strong></p><p>Cisplatin can destroy cells in your body that may cause certain types of cancer (tumour of testis, tumour of ovary, tumour of the bladder, head and neck epithelial tumour, lung cancer and for cervical cancer in combination with radiotherapy).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Cisplatin Sterile Concentrate </strong></p><ul><li>if you are allergic to cisplatin or to any of the other ingredients of this medicine (listed in section 6)</li><li>if you have had hypersensitivity to similar anti-cancer medicines in the past</li><li>if you have severe kidney disease</li><li>if you have hearing difficulties</li><li>if you have very low numbers of blood cells (called &lsquo;myelosuppression&rsquo;), (your doctor will check this with a blood test)</li><li>if you are dehydrated</li><li>if you are pregnant or breast-feeding</li><li>if you need to have a vaccine for &lsquo;yellow fever&rsquo;</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Cisplatin Sterile Concentrate:</p><ul><li>if you have any symptoms of nerve damage (peripheral neuropathy) such as pins and needles, numbness or poor sense of touch</li><li>if you have had radiation therapy to your head</li><li>Cases of delayed-onset hearing loss have been reported in the paediatric population. Long term follow-up in this population is recommended</li></ul><p>&nbsp;</p><p><strong>Other medicines and Cisplatin Sterile Concentrate</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking/ using, have recently taken/ used or might take/ use any other medicines, for example:</p><ul><li>some antibiotics, such as cephalosporins, aminoglycosides and amphotericin B and some substances used in medical imaging may make the side effects of cisplatin worse; particularly kidney problems</li><li>some water tablets called loop diuretics, antibiotics called aminoglycosides and an anti-cancer medicine called ifosfamide may make the hearing loss side effect of cisplatin worse</li><li>bleomycin (anti-cancer medicine), methotrexate (used to treat cancer or arthritis) and paclitaxel (anti-cancer medicine) may produce more side effects if cisplatin is also being used</li><li>the effectiveness of oral anticoagulants such as coumarins/warfarin may be affected. Your doctor will monitor with blood tests</li><li>use of certain antihistamines may hide the symptoms of balance changes (such as dizziness or tinnitus)</li><li>the effectiveness of medicines used for the treatment of convulsions (e.g. phenytoin) may be reduced, so blood levels may need to be checked</li><li>cisplatin may make the side effects of the anti-cancer medicine ifosfamide worse</li></ul><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><u>Pregnancy</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>&nbsp;</p><p>You must use reliable contraception during and for at least 29 weeks (at least 7 months) after the last dose.</p><p>&nbsp;</p><p>Treatment with cisplatin can potentially cause permanent sterility in men.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Do not use this medicine if you are breast-feeding and for 4 weeks after treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Men with female partners of childbearing potential should be advised to use effective contraception during treatment with cisplatin and for at least 17 weeks (at least 4 months) after the last dose.</p><p>&nbsp;</p><p>Both men and women should seek advice on fertility preservation before treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use machines if you experience any side effect which may lessen your ability to do so.</p><p>&nbsp;</p><p><strong>Cisplatin Sterile Concentrate contains sodium</strong></p><p>Cisplatin 50 mg/50 ml (1 mg/ml) Sterile Concentrate for Solution for Infusion contains 177 mg of sodium (main component of cooking/table salt) in 50 ml vial. This is equivalent to 8.9% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>This medicine may be prepared with a solution that contains sodium. This should be taken into additional consideration if you are on a low salt (sodium) diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Cisplatin Sterile Concentrate </strong></p><ul><li>if you are allergic to cisplatin or to any of the other ingredients of this medicine (listed in section 6)</li><li>if you have had hypersensitivity to similar anti-cancer medicines in the past</li><li>if you have severe kidney disease</li><li>if you have hearing difficulties</li><li>if you have very low numbers of blood cells (called &lsquo;myelosuppression&rsquo;), (your doctor will check this with a blood test)</li><li>if you are dehydrated</li><li>if you are pregnant or breast-feeding</li><li>if you need to have a vaccine for &lsquo;yellow fever&rsquo;</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Cisplatin Sterile Concentrate:</p><ul><li>if you have any symptoms of nerve damage (peripheral neuropathy) such as pins and needles, numbness or poor sense of touch</li><li>if you have had radiation therapy to your head</li><li>Cases of delayed-onset hearing loss have been reported in the paediatric population. Long term follow-up in this population is recommended</li></ul><p>&nbsp;</p><p><strong>Other medicines and Cisplatin Sterile Concentrate</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking/ using, have recently taken/ used or might take/ use any other medicines, for example:</p><ul><li>some antibiotics, such as cephalosporins, aminoglycosides and amphotericin B and some substances used in medical imaging may make the side effects of cisplatin worse; particularly kidney problems</li><li>some water tablets called loop diuretics, antibiotics called aminoglycosides and an anti-cancer medicine called ifosfamide may make the hearing loss side effect of cisplatin worse</li><li>bleomycin (anti-cancer medicine), methotrexate (used to treat cancer or arthritis) and paclitaxel (anti-cancer medicine) may produce more side effects if cisplatin is also being used</li><li>the effectiveness of oral anticoagulants such as coumarins/warfarin may be affected. Your doctor will monitor with blood tests</li><li>use of certain antihistamines may hide the symptoms of balance changes (such as dizziness or tinnitus)</li><li>the effectiveness of medicines used for the treatment of convulsions (e.g. phenytoin) may be reduced, so blood levels may need to be checked</li><li>cisplatin may make the side effects of the anti-cancer medicine ifosfamide worse</li></ul><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><u>Pregnancy</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>&nbsp;</p><p>You must use reliable contraception during and for at least 29 weeks (at least 7 months) after the last dose.</p><p>&nbsp;</p><p>Treatment with cisplatin can potentially cause permanent sterility in men.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Do not use this medicine if you are breast-feeding and for 4 weeks after treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Men with female partners of childbearing potential should be advised to use effective contraception during treatment with cisplatin and for at least 17 weeks (at least 4 months) after the last dose.</p><p>&nbsp;</p><p>Both men and women should seek advice on fertility preservation before treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use machines if you experience any side effect which may lessen your ability to do so.</p><p>&nbsp;</p><p><strong>Cisplatin Sterile Concentrate contains sodium</strong></p><p>Cisplatin 50 mg/50 ml (1 mg/ml) Sterile Concentrate for Solution for Infusion contains 177 mg of sodium (main component of cooking/table salt) in 50 ml vial. This is equivalent to 8.9% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>This medicine may be prepared with a solution that contains sodium. This should be taken into additional consideration if you are on a low salt (sodium) diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If any of the following happen, tell your doctor immediately:</strong></p><ul><li>severe allergic reaction - you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), flushing and you may feel you are going to faint</li><li>severe chest pains possibly radiating to the jaw or arm with sweating, breathlessness and nausea (heart attack)</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or swelling at the injection site during the injection (may be due to the injection not going into the vein properly, which can lead to serious damage to the tissues around the injection site)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; brain dysfunction (confusion, slurred speech, sometimes blindness, memory loss and paralysis)</p><p>&nbsp;</p><p>These are serious side effects. You may need urgent medical attention.</p><p>&nbsp;</p><p>Very common: may affect more than 1 in 10 people:</p><ul><li>decrease in bone marrow function (which can affect the production of blood cells)</li><li>decrease in white blood cells, which makes infections more likely (leukopenia)</li><li>decrease in blood platelets, which increases the risk of bruising and bleeding (thrombocytopenia)</li><li>reduction of red blood cells which can cause weakness and your skin to look pale (anaemia)</li><li>reduced level of sodium in the blood</li><li>high temperature</li></ul><p>&nbsp;</p><p>Common: may affect up to 1 in 10 people:</p><ul><li>severe pain or swelling in either of your legs, chest pain, or difficulty breathing (possibly indicating harmful blood clots in a vein)</li></ul><ul><li>fast, irregular or slow heart beats</li><li>sepsis (blood poisoning)</li></ul><p>&nbsp;</p><p>Uncommon: may affect up to 1 in 100 people:</p><ul><li>severe allergic reaction (see above)</li><li>damage to the ear (ototoxicity)</li><li>reduced level of magnesium in the blood</li><li>abnormal sperm production</li></ul><p>&nbsp;</p><p>Rare: may affect up to 1 in 1,000 people:</p><ul><li>increased risk of acute leukaemia</li><li>seizures (fits)</li><li>fainting, headache, confusion and loss of vision</li><li>loss of certain types of brain function, including brain dysfunction characterised by spasms and reduced level of consciousness</li><li>heart attack</li><li>inflammation of mucous membranes of the mouth (stomatitis).</li><li>peripheral neuropathy of the sensory nerves, characterised by tickling, itching or tingling without cause and sometimes with loss of taste, touch, sight, sudden shooting pains from the neck through the back and into the legs when bending forward</li></ul><p>&nbsp;</p><p>Very rare: may affect up to 1 in 10,000 people:</p><ul><li>heart arrest</li></ul><p>&nbsp;</p><p>Not known: frequency cannot be estimated from the available data:</p><ul><li>signs of infection such as fever or sore throat</li><li>haemolytic anaemia</li><li>inappropriate release of vasopressin hormone (ADH) which may lead to low sodium in the blood and water retention</li><li>blood amylase (enzyme) increased</li><li>dehydration</li><li>reduced level of calcium, phosphate, potassium in the blood</li><li>high level of uric acid in the blood</li><li>muscle cramping</li><li>spinal disease which may cause a sensation of electric shocks passing into your limbs</li><li>loss of taste</li><li>problems with your eyesight (blurred vision, odd colours, loss of vision or eye pain)</li><li>ringing in the ears or deafness</li><li>heart problems</li><li>unusually cold or white hands and feet</li><li>tingling, numbness or tremor in your hands, feet, arms or legs</li><li>persistent headache</li><li>feeling or being sick</li><li>loss of appetite, anorexia</li><li>hiccups</li><li>diarrhoea</li><li>liver enzymes increased, bilirubin increased</li><li>difficulty breathing</li><li>problems with your kidneys or urine</li><li>hair loss</li><li>rash</li><li>extreme tiredness/weakness</li><li>swelling or soreness where the injection was given</li><li>cramps or spasms</li><li>burning or prickling sensation</li><li>unexpected bruising or bleeding</li><li>haemolytic uremic syndrome which may cause changes to the kidneys and blood</li></ul><p><strong>&nbsp;</strong></p><p>Cisplatin may lead to problems with your blood, liver and kidneys. Your doctor will take blood samples to check for these problems.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p>To Report side effects:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States:</strong></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p><strong>Expiry</strong></p><p>This medicine must not be used after the expiry date which is stated on the vial label and carton after &#39;EXP&#39;. Where only a month and year is stated, the expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shelf life 24 months.</p><p><strong>&nbsp;</strong></p><p><strong>Storage</strong></p><p>Do not store above 25&deg;C. Do not refrigerate or freeze. Keep container in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Prepared infusions should be used immediately, however, if this is not possible they can be stored for up to 14 days provided they have been prepared in a way to exclude microbial contamination. The prepared infusions should not be refrigerated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cisplatin. &nbsp;Each millilitre (ml) of solution contains 1 milligram (mg) of cisplatin.</p><p>&nbsp;</p><p>The other ingredients are mannitol, sodium chloride, dilute hydrochloric acid and water for injections (see section 2 &lsquo;Cisplatin Sterile Concentrate contains sodium&rsquo;)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cisplatin Sterile Concentrate is a clear, colourless to pale yellow concentrate for solution for infusion which comes in glass containers called vials. 

Supplied in packs containing:
1 x 50 mg/50 ml vial 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Hospira UK Limited</p><p>Horizon</p><p>Honey Lane</p><p>Hurley</p><p>Maidenhead</p><p>SL6 6RJ</p><p>United Kingdom</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>Hospira Australia Pty Ltd, 1-5, 7-23 and 25-39 Lexia Place, Mulgrave, VIC 3170, Australia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يشكل سيسبلاتين جزءًا من مجموعة أدوية تسمى مثبطات نمو الخلايا، وتُستخدم في علاج السرطان. يمكن استخدام سيسبلاتين بمفرده، لكن الشائع أكثر أن يُستخدم سيسبلاتين بالتزامن مع غيره من مثبطات نمو الخلايا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم تُستخدم</strong></p><p dir="RTL">يمكن أن يدمر سيسبلاتين خلايا في جسمك قد تسبب أنواعًا معينة من السرطان (ورم الخصية، وورم المبيض، وورم المثانة، وورم الظهارة في الرأس والعنق، وسرطان الرئة، ويُستخدم لعلاج سرطان عنق الرحم بالتزامن مع العلاج الإشعاعي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>موانع استعمال ركازة سيسبلاتين المعقمة </strong></p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه سيسبلاتين أو تجاه أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في الماضي بفرط الحساسية تجاه أدوية مشابهة مضادة للسرطان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كلى شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صعوبات في السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كان عدد خلايا دمك منخفضًا جدًا (يسمى &quot;كبت نقى العظم&quot;)، (سيتحقق طبيبك من ذلك بإجراء فحص دم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الجفاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان يجب أن تتلقى لقاح &quot;الحمى الصفراء&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ركازة سيسبلاتين المعقمة</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام ركازة سيسبلاتين المعقمة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت مصابًا بأي أعراض لتلف الأعصاب (الاعتلال العصبي المحيطي) مثل الشكشكة والوخز، أو الخدر، أو ضعف حاسة اللمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لعلاج إشعاعي للرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وردت بلاغات عن حالات تأخر لديها ظهور الإصابة بفقدان السمع في فئة الأطفال. يوصى بالمتابعة طويلة المدى لهذه الفئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول/تستخدم أو تناولت/استخدمت مؤخرًا أو قد تتناول/تستخدم أي أدوية أخرى، على سبيل المثال:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية، مثل السيفالوسبورينات، والأمينوجليكوزيدات، وأمفوتيريسين ب، وبعض المواد المستخدمة في التصوير الطبي قد تسبب تفاقم الأعراض الجانبية لسيسبلاتين؛ وخاصة مشكلات الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أقراص الماء التي تسمى مدرات البول العروية، والمضادات الحيوية التي تسمى الأمينوجليكوزيدات، ودواء مضاد للسرطان يسمى إيفوسفاميد قد تسبب تفاقم العرض الجانبي لسيسبلاتين المتمثل في فقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب بليومايسين (دواء مضاد للسرطان)، وميثوتريكسات (يستخدم لعلاج السرطان أو التهاب المفاصل)، وباكليتاكسيل (دواء مضاد للسرطان) أعراضًا جانبية إضافية في حالة استخدام سيسبلاتين مع هذه الأدوية أيضًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتأثر فعالية مضادات التجلط، مثل الكومارينات/الوارفارين، التي تؤخذ عن طريق الفم. سيراقب طبيبك ذلك عن طريق فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي استخدام بعض مضادات الهيستامين إلى إخفاء أعراض التغيرات في التوازن (مثل الدوار أو طنين الأذن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تنخفض فعالية الأدوية المستخدمة لعلاج الاختلاجات (مثل فينيتوين)، لذلك قد يلزم التحقق من مستوياتها في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب سيسبلاتين تفاقم الأعراض الجانبية لدواء إيفوسفاميد المضاد للسرطان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><u>الحمل </u></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو إذا كنتِ تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ استخدام وسائل منع حمل موثوقة خلال ۲۹ أسبوعًا (٧ أشهر على الأقل) بعد تلقي الجرعة الأخيرة، والمدة لا تقل عن ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحتمل أن يسبب العلاج بسيسبلاتين عقمًا دائمًا لدى الرجال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا تستخدمي هذا الدواء إذا كنتِ ترضعين رضاعة طبيعية ولمدة ٤ أسابيع بعد تلقي العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">ينبغي أن يُنصح الرجال الذين لديهم زوجات قادرات على الإنجاب باستخدام وسائل منع حمل فعالة في أثناء العلاج بسيسبلاتين ولمدة لا تقل عن ۱٧ أسبوعًا (٤ أشهر على الأقل) بعد تلقي الجرعة الأخيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي لكل من الرجال والسيدات طلب المشورة حول الحفاظ على الخصوبة قبل تلقي العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ركازة سيسبلاتين المعقمة على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقد مركبة ولا تستخدم الآلات إذا كنت تعاني من أي عرض جانبي قد يقلل قدرتك على القيام بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات ركازة سيسبلاتين المعقمة</strong></p><p dir="RTL"><strong>تحتوي ركازة سيسبلاتين المعقمة على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ركازة سيسبلاتين المعقمة ٥٠ ملجم/٥٠ مل (١ ملجم/مل) المخصصة لتحضير محلول للتسريب تحتوي على ١٧٧ ملجم من الصوديوم (المكون الأساسي لملح الطعام/المائدة) في قارورة سعة ٥٠ مل. وهذا يكافئ ٨٫٩ ٪ من الحد الأقصى للمدخول الغذائي اليومي الموصى به من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تحضير هذا الدواء بمحلول يحتوي على الصوديوم. ينبغي مراعاة ذلك بعناية أكبر إذا كنت تتبع حمية غذائية منخفضة الملح (الصوديوم).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>موانع استعمال ركازة سيسبلاتين المعقمة </strong></p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه سيسبلاتين أو تجاه أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في الماضي بفرط الحساسية تجاه أدوية مشابهة مضادة للسرطان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كلى شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صعوبات في السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كان عدد خلايا دمك منخفضًا جدًا (يسمى &quot;كبت نقى العظم&quot;)، (سيتحقق طبيبك من ذلك بإجراء فحص دم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الجفاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان يجب أن تتلقى لقاح &quot;الحمى الصفراء&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ركازة سيسبلاتين المعقمة</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام ركازة سيسبلاتين المعقمة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت مصابًا بأي أعراض لتلف الأعصاب (الاعتلال العصبي المحيطي) مثل الشكشكة والوخز، أو الخدر، أو ضعف حاسة اللمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لعلاج إشعاعي للرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وردت بلاغات عن حالات تأخر لديها ظهور الإصابة بفقدان السمع في فئة الأطفال. يوصى بالمتابعة طويلة المدى لهذه الفئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول/تستخدم أو تناولت/استخدمت مؤخرًا أو قد تتناول/تستخدم أي أدوية أخرى، على سبيل المثال:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية، مثل السيفالوسبورينات، والأمينوجليكوزيدات، وأمفوتيريسين ب، وبعض المواد المستخدمة في التصوير الطبي قد تسبب تفاقم الأعراض الجانبية لسيسبلاتين؛ وخاصة مشكلات الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أقراص الماء التي تسمى مدرات البول العروية، والمضادات الحيوية التي تسمى الأمينوجليكوزيدات، ودواء مضاد للسرطان يسمى إيفوسفاميد قد تسبب تفاقم العرض الجانبي لسيسبلاتين المتمثل في فقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب بليومايسين (دواء مضاد للسرطان)، وميثوتريكسات (يستخدم لعلاج السرطان أو التهاب المفاصل)، وباكليتاكسيل (دواء مضاد للسرطان) أعراضًا جانبية إضافية في حالة استخدام سيسبلاتين مع هذه الأدوية أيضًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتأثر فعالية مضادات التجلط، مثل الكومارينات/الوارفارين، التي تؤخذ عن طريق الفم. سيراقب طبيبك ذلك عن طريق فحوصات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي استخدام بعض مضادات الهيستامين إلى إخفاء أعراض التغيرات في التوازن (مثل الدوار أو طنين الأذن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تنخفض فعالية الأدوية المستخدمة لعلاج الاختلاجات (مثل فينيتوين)، لذلك قد يلزم التحقق من مستوياتها في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب سيسبلاتين تفاقم الأعراض الجانبية لدواء إيفوسفاميد المضاد للسرطان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><u>الحمل </u></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو إذا كنتِ تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ استخدام وسائل منع حمل موثوقة خلال ۲۹ أسبوعًا (٧ أشهر على الأقل) بعد تلقي الجرعة الأخيرة، والمدة لا تقل عن ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحتمل أن يسبب العلاج بسيسبلاتين عقمًا دائمًا لدى الرجال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا تستخدمي هذا الدواء إذا كنتِ ترضعين رضاعة طبيعية ولمدة ٤ أسابيع بعد تلقي العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">ينبغي أن يُنصح الرجال الذين لديهم زوجات قادرات على الإنجاب باستخدام وسائل منع حمل فعالة في أثناء العلاج بسيسبلاتين ولمدة لا تقل عن ۱٧ أسبوعًا (٤ أشهر على الأقل) بعد تلقي الجرعة الأخيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي لكل من الرجال والسيدات طلب المشورة حول الحفاظ على الخصوبة قبل تلقي العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ركازة سيسبلاتين المعقمة على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقد مركبة ولا تستخدم الآلات إذا كنت تعاني من أي عرض جانبي قد يقلل قدرتك على القيام بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات ركازة سيسبلاتين المعقمة</strong></p><p dir="RTL"><strong>تحتوي ركازة سيسبلاتين المعقمة على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ركازة سيسبلاتين المعقمة ٥٠ ملجم/٥٠ مل (١ ملجم/مل) المخصصة لتحضير محلول للتسريب تحتوي على ١٧٧ ملجم من الصوديوم (المكون الأساسي لملح الطعام/المائدة) في قارورة سعة ٥٠ مل. وهذا يكافئ ٨٫٩ ٪ من الحد الأقصى للمدخول الغذائي اليومي الموصى به من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تحضير هذا الدواء بمحلول يحتوي على الصوديوم. ينبغي مراعاة ذلك بعناية أكبر إذا كنت تتبع حمية غذائية منخفضة الملح (الصوديوم).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذ</strong><strong>ا </strong><strong>حدث أي مما يلي، فأخبر طبيبك على الفور:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد &ndash; قد تصاب بطفح جلدي مفاجئ مثير للحكة (شرى)، وتورم في اليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين أو الفم أو الحلق (مما قد يسبب صعوبة في البلع أو التنفس)، والاحمرار، وقد تشعر أنك على وشك الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة في الصدر يحتمل أن تنتشر إلى الفك أو الذراع مع العرق وانقطاع التنفس والغثيان (أزمة قلبية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تورم في موضع الحقن أثناء الحقن (قد يكون بسبب عدم دخول الحقنة في الوريد بشكل صحيح، مما يمكن أن يؤدي إلى تلف خطير في الأنسجة المحيطة بموضع الحقن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; خلل وظيفي في المخ (الارتباك، وتداخل الكلام، وأحيانًا العمى، وفقدان الذاكرة، والشلل)</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه أعراض جانبية خطيرة. وقد تحتاج إلى رعاية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في وظائف نخاع العظم (مما قد يؤثر على إنتاج خلايا الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء، مما يزيد احتمالية الإصابة بالعدوى (قلة الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية، مما يزيد خطر الإصابة بالتكدم والنزيف (قلة الصفيحات الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء، مما يمكن أن يسبب الضعف وشحوب جلدك (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصوديوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تورم شديد في أي من ساقيك، أو ألم الصدر، أو صعوبة التنفس (ربما يشير ذلك إلى وجود جلطات دموية ضارة في أحد الأوردة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة أو غير منتظمة أو بطيئة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنتان (تسمم الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد (انظر أعلاه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تلف في الأذن (سمية الأذن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى المغنيسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في إنتاج الحيوانات المنوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر الإصابة بابيضاض الدم الحاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات (التشنجات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، والصداع، والارتباك، وفقدان الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان أنواع معينة من وظائف المخ، بما في ذلك خلل المخ الوظيفي الذي يتسم بالتشنجات وانخفاض مستوى الوعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزمة القلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المخاطية في الفم (التهاب الفم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاعتلال العصبي المحيطي في الأعصاب الحسية الذي يتسم بشعور بالدغدغة أو الحكة أو الوخز دون سبب وأحيانًا يكون مصحوبًا بفقدان حاسة التذوق واللمس والبصر، وآلام حارقة مفاجئة تمتد من الرقبة عبر الظهر وحتى الساقين عند الانحناء للأمام</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة جدًا: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠٠ شخص:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة قلبية</p><p dir="RTL">&nbsp;</p><p dir="RTL">ذات معدل تكرار غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات العدوى مثل الحمى أو احتقان الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم الانحلالي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفراز هرمون فازوبريسين (ADH) بمعدل غير ملائم مما قد يؤدي إلى انخفاض مستوى الصوديوم في الدم والاحتفاظ بالماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الأميلاز (إنزيم) في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الكالسيوم، الفوسفات، البوتاسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى حمض اليوريك في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشد العضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الحبل الشوكي الذي قد يسبب إحساسًا بمرور صدمات كهربائية في أطرافك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الإبصار (تغيم الرؤية، أو رؤية ألوان غريبة، أو فقدان الرؤية، أو ألم العين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين في الأذنين أو صمم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برودة أو ابيضاض اليدين والقدمين بشكل غير طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز، أو الخدر، أو الرعاش في يديك أو قدميك أو ذراعيك أو ساقيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع المستمر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، القهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الزغطة (الفواق أو الحازوقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات إنزيمات الكبد، ارتفاع مستوى البيليروبين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكلى أو البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب/الضعف الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو وجع في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات أو تقلصات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالحرقان أو الشكشكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التكدم أو النزيف المفاجئ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة انحلال الدم اليوريمي التي قد تسبب تغيرات بالكليتين والدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب سيسبلاتين مشكلات في دمك وكبدك وكليتيك. سيأخذ طبيبك عينات دم للتحقق من عدم وجود هذه المشكلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي أعراض جانبية محتمل حدوثها غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><ul><li dir="RTL">مركز الاتصال الموحد: ١٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:342px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتهاء الصلاحية</strong></p><p dir="RTL">يجب عدم استخدام هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القارورة والعبوة الكرتونية بعد الرمز &quot;EXP&quot;. في حالة ذكر الشهر والعام فقط فإن تاريخ انتهاء الصلاحية يشير إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة الصلاحية ٢٤ شهرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التخزين</strong></p><p dir="RTL">لا تخزنه في درجة حرارة أعلى من ٢٥ درجة مئوية. لا تضعه في البراد (الثلاجة) أو تجمده. احفظ الحاوية في العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام الكميات المعدَّة للتسريب فورًا، لكن إذا لم يكن هذا ممكنًا يمكن تخزينها لفترة تصل إلى ١٤ يومًا بشرط تحضيرها بطريقة تمنع التلوث الميكروبي. وينبغي عدم وضع التحضيرات المعدَّة للتسريب في الثلاجة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيسبلاتين. كل ملليلتر (مل) من المحلول يحتوي على واحد مليجرام (ملجم) من سيسبلاتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي مانيتول، وكلوريد الصوديوم، وحمض الهيدروكلوريك المخفف، وماء للحقن (انظر القسم ٢ &quot;تحتوي ركازة سيسبلاتين المعقمة على الصوديوم&quot;).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ركازة سيسبلاتين المعقمة هي ركازة صافية تتراوح من عديمة اللوح إلى اللون الأصفر الفاتح ومخصصة لتحضير محلول للتسريب، وتتوفر في حاويات زجاجية تسمى قوارير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر هذا الدواء في عبوات تحتوي على:</p><p dir="RTL">قارورة واحدة &times; ٥٠ ملجم/٥٠ مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Hospira UK Limited</p><p dir="RTL">&nbsp;Horizon</p><p dir="RTL">&nbsp;Honey Lane</p><p dir="RTL">&nbsp;Hurley</p><p dir="RTL">&nbsp;Maidenhead</p><p dir="RTL">&nbsp;SL6 6RJ</p><p dir="RTL">United Kingdom<strong>، </strong>المملكة المتحدة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">Hospira Australia Pty Ltd, 1-5, 7-23 and 25-39 Lexia Place, Mulgrave, VIC 3170, Australia، أستراليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر/أيلول ۲۰۲۳
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cisplatin 1 mg/ml sterile concentrate 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1 ml of concentrate for solution for infusion contains 1 mg of cisplatin.

Each single vial of 50 ml concentrate for solution for infusion contains 50 mg of cisplatin.  

Excipients with known effect:
Cisplatin 50 mg/50 ml (1 mg/ ml) concentrate for solution for infusion contains 177 mg of sodium in each 50 ml vial.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Clear, colourless to pale yellow solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cisplatin is intended for the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced or metastasised testicular cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced or metastasised ovarian cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced or metastasised bladder carcinoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced or metastasised squamous cell carcinoma of the head and neck</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced or metastasised non-small cell lung carcinoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced or metastasised small cell lung carcinoma</p><p>&nbsp;</p><p>Cisplatin is indicated in the treatment of cervical carcinoma in combination with other chemotherapeutics or with radiotherapy.</p><p>&nbsp;</p><p>Cisplatin can be used as monotherapy and in combination therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><strong><u>Adults and</u></strong><strong><u> Paediatric</u></strong><strong><u> population</u></strong></p><p>&nbsp;</p><p>The cisplatin dosage depends on the primary disease, the expected reaction, and on whether cisplatin is used for monotherapy or as a component of combination chemotherapy. The dosage directions are applicable for both adults and children.</p><p>&nbsp;</p><p>For <u>monotherapy</u>, the following two dosage regimens are recommended:</p><p>Single dose of 50 to 120 mg/m<sup>2</sup> body surface every 3 to 4 weeks;</p><p>15 to 20 mg/m<sup>2</sup>/day for five days, every 3 to 4 weeks</p><p>&nbsp;</p><p>If cisplatin is used in <u>combination therapy</u>, the dose of cisplatin must be reduced. A typical dose is 20mg/m<sup>2</sup> or more once every 3 to 4 weeks.</p><p>&nbsp;</p><p>For treatment of cervical cancer cisplatin is used in combination with radiotherapy. A typical dose is 40 mg/m<sup>2</sup> weekly for 6 weeks.</p><p>&nbsp;</p><p>For warning and precautions to be considered prior to the start of the next treatment cycle (see section 4.4).</p><p>&nbsp;</p><p>In patients with renal dysfunction or bone marrow depression, the dose should be reduced adequately (see section 4.3).</p><p>&nbsp;</p><p>The cisplatin solution for infusion prepared according to instructions (see section 6.6) should be administered by intravenous infusion over a period of 6 to 8 hours.</p><p>&nbsp;</p><p>Adequate hydration must be maintained from 2 to 12 hours prior to administration until minimum 6 hours after the administration of cisplatin. Hydration is necessary to cause sufficient diuresis during and after treatment with cisplatin. It is realised by intravenous infusion of one of the following solutions:</p><p>Sodium chloride solution: 0.9%</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Cisplatin 1 mg/ml sterile concentrate is to be diluted before administration. For instructions for dilution of the product before administration see section 6.6.</p><p>&nbsp;</p><p>The diluted solution should be administered only intravenously by infusion (see below). For administration, any device containing aluminium that may come in contact with cisplatin (sets for intravenous infusion, needles, catheters, syringes) must be avoided.</p><p><u>&nbsp;</u></p><p>Hydration prior to treatment with cisplatin:</p><p>&nbsp;</p><p>Intravenous infusion of 100 to 200ml/Hour for a period of 6 to 12 hours, with a total amount of at least 1 litre.</p><p>&nbsp;</p><p>Hydration after termination of the administration of cisplatin:</p><p>&nbsp;</p><p>Intravenous infusion of another 2 litres at a rate of 100 to 200 ml per hour for a period of 6 to 12 hours.</p><p>&nbsp;</p><p>Forced diuresis may be required should the urine secretion be less than 100 to 200 ml/hour after hydration. Forced diuresis may be realised by intravenously administering 37.5g mannitol as a 10% solution (375 ml mannitol solution 10%), or by administration of a diuretic if the kidney functions are normal.</p><p>&nbsp;</p><p>The administration of mannitol or a diuretic is also required when the administrated cisplatin dose is higher than 60 mg/m<sup>2</sup> of body surface.</p><p>&nbsp;</p><p>It is necessary that the patient drinks large quantities of liquids for 24 hours after the cisplatin infusion to ensure adequate urine secretion.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cisplatin or to any of the excipients listed in section 6.1.

Cisplatin may give allergic reactions in some patients. Use is contraindicated in those patients with a history of allergic reaction to cisplatin or other platinum containing compounds, or any component of the formulation. Cisplatin induces nephrotoxicity which is cumulative. It is therefore contraindicated in patients with pre-existing renal impairment.

Cisplatin has also been shown to be cumulatively neurotoxic (in particular ototoxic) and should not be given to patients with pre-existing hearing impairment. Cisplatin is also contraindicated in myelosuppressed patients and those who are dehydrated.

Patients receiving cisplatin should not breast feed (see section 4.6).

Concurrent administration of yellow fever vaccine is contraindicated.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This agent should only be administered under the direction of oncologists in specialist units under conditions permitting adequate monitoring and surveillance. Supportive equipment should be available to control anaphylactic reactions.</p><p>&nbsp;</p><p>Cisplatin reacts with metallic aluminium to form a black precipitate of platinum. All aluminium containing IV sets, needles, catheters and syringes should be avoided.</p><p>&nbsp;</p><p>The solution for infusion should not be mixed with other drugs or additives.</p><p>&nbsp;</p><p>Appropriate monitoring and management of the treatment and its complications are only possible if adequate diagnosis and exact treatment conditions are available.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Nephrotoxicity</u></p><p>&nbsp;</p><p>Cisplatin produces severe cumulative nephrotoxicity which may be potentiated by aminoglycoside antibiotics. The serum creatinine, plasma urea or creatinine clearance and magnesium, sodium potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. Cisplatin should not be given more frequently than once every 3-4 weeks.</p><p>&nbsp;</p><p>A urine output of 100 ml/hour or greater will tend to minimise cisplatin nephrotoxicity. This can be accomplished by prehydration with 2 litres of an appropriate intravenous solution, and similar post cisplatin hydration (recommended 2,500 ml/m<sup>2</sup>/24 hours). If vigorous hydration is insufficient to maintain adequate urinary output, an osmotic diuretic may be administered (e.g., mannitol).&nbsp;</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Neuropathies</u></p><p>&nbsp;</p><p>Severe cases of neuropathies have been reported.</p><p>&nbsp;</p><p>These neuropathies may be irreversible and may manifest by paresthesia, areflexia and a proprioceptive loss and a loss of vibration perception. A loss of motor function has also been reported. A neurological examination must be carried out at regular intervals.</p><p>&nbsp;</p><p>Neurotoxicity appears to be cumulative. Prior to each course, the absence of symptoms of peripheral neuropathy should be established.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Ototoxicity</u></p><p>&nbsp;</p><p>Ototoxicity has been observed in up to 31% of patients treated with a single dose of cisplatin 50 mg/m<sup>2</sup>, and is manifested by tinnitus and/or hearing loss in the high frequency range (4000 to 8000 Hz). Decreased ability to hear conversational tones may occur occasionally. Ototoxic effect may be more pronounced in children receiving cisplatin. Cases of delayed-onset hearing loss have been reported in the paediatric population. Long term follow-up in this population is recommended. Hearing loss can be unilateral or bilateral and tends to become more frequent and severe with repeated doses; however, deafness after initial dose of cisplatin has been reported rarely. Ototoxicity may be enhanced with prior simultaneous cranial irradiation and may be related to peak plasma concentration of cisplatin.&nbsp; It is unclear whether cisplatin induced ototoxicity is reversible. Careful monitoring by audiometry should be performed prior to initiation of therapy and prior to subsequent doses of cisplatin. Vestibular toxicity has also been reported. (see section 4.8).</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Allergic phenomena</u></p><p>&nbsp;</p><p>Anaphylactic-like reactions to cisplatin have been reported. These reactions have occurred within minutes of administration to patients with prior exposure to cisplatin and have been alleviated by administration of adrenaline, steroids and antihistamines.</p><p>&nbsp;</p><p>As with other platinum-based products, hypersensitivity reactions appearing in most cases during perfusion may occur, and necessitate discontinuation of the perfusion and an appropriate symptomatic treatment.&nbsp; Cross reactions, sometimes fatal, have been reported with all the platinum compounds (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Hepatic function and</u><u> haematological</u><u> formula</u></p><p>&nbsp;</p><p>The haematological formula and hepatic function must be monitored at regular intervals.</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Carcinogenic potential</u></p><p>&nbsp;</p><p>In humans, in rare cases the appearance of acute leukaemia has coincided with the use of cisplatin, which was in general associated with other leukaemogenic agent.</p><p>&nbsp;</p><p>Cisplatin has been shown to be teratogenic, embryotoxic and carcinogenic in mice and rats.</p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Injection site reactions</u></p><p>&nbsp;</p><p>Injection site reactions may occur during the administration of cisplatin. Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during drug administration. A specific treatment for extravasation reactions is unknown at this time.</p><p>&nbsp;</p><p><u>WARNINGS</u></p><p>&nbsp;</p><p>This cytostatic agent had a more marked toxicity than is usually found in antineoplastic chemotherapy.</p><p>&nbsp;</p><p>Renal toxicity, which is above all cumulative, is severe and requires particular precautions during administration (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>Nausea and vomiting may be intense and require adequate antiemetic treatment.&nbsp;</p><p>&nbsp;</p><p>Close supervision must also be carried out with regard to ototoxicity, myelodepression and anaphylactic reactions (see section 4.8).</p><p>&nbsp;</p><p><u>Preparation of the intravenous solution</u></p><p><u>&nbsp;</u></p><p><em><u>Warning</u></em></p><p>&nbsp;</p><p>As with all other potentially toxic products, precautions are essential when handling the cisplatin solution. Skin lesions are possible in the event of accidental exposure to the product. It is advisable to wear gloves. In the event the cisplatin solution comes into contact with the skin or mucous membranes, wash the skin or mucous membranes vigorously with soap and water.</p><p>&nbsp;</p><p>Conforming to the procedures appropriate for the manipulation and elimination of cytostatic agents is recommended.</p><p>&nbsp;</p><p>Before administering the solution to the patient, verify the clarity of the solution and the absence of particles</p><p>&nbsp;</p><p><u>Excipient information</u></p><p>&nbsp;</p><p>Cisplatin 50 mg/50 ml (1 mg/ ml) concentrate for solution for infusion contains 177 mg of sodium in each 50 ml vial, equivalent to 8.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>&nbsp;</p><p>Cisplatin may be further prepared for administration with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Nephrotoxic substances:</strong></p><p>Concomitant administration of nephrotoxic (e.g. cephalosporins, aminoglycosides, amphotericin B or contrast media) or ototoxic (e.g. aminoglycosides) medicinal products will potentiate the toxic effect of cisplatin on the kidneys. During or after treatment with cisplatin caution is advised with predominantly renal eliminated substances, e.g. cytostatic agents such as bleomycin and methotrexate, because of potentially reduced renal elimination.</p><p>&nbsp;</p><p>The renal toxicity of ifosfamide may be greater when used with cisplatin or in patients who have previously been given cisplatin.</p><p>&nbsp;</p><p><u>Renally excreted drugs:</u></p><p>&nbsp;</p><p>Reduction of the blood&rsquo;s lithium values was noticed in a few cases after treatment with cisplatin combined with bleomycin and etoposide. It is therefore recommended to monitor the lithium values.</p><p>&nbsp;</p><p><strong>Ototoxic substances:</strong></p><p>Concomitant administration of ototoxic (e.g. aminoglycosides, loop diuretics) medicinal products will potentiate the toxic effect of cisplatin on auditory function. Except for patients receiving doses of cisplatin exceeding 60 mg/m<sup>2</sup>, whose urine secretion is less than 1000 ml per 24 hours, no forced diuresis with loop diuretics should be applied in view of possible damage to the kidney tract and ototoxicity.</p><p>&nbsp;</p><p><u>Ifosfamide may increase hearing loss due to cisplatin.</u></p><p>&nbsp;</p><p><strong>Weakened live vaccines:</strong></p><p>Yellow fever vaccine is strictly contraindicated because of the risk of fatal systemic vaccinal disease (see section 4.3). In view of the risk of generalised illness, it is advisable to use an inactive vaccine if available.</p><p>&nbsp;</p><p><strong>Oral anticoagulants:</strong></p><p>In the event of simultaneous use of oral anticoagulants such as coumarins/warfarin, it is advisable to regularly check the INR.</p><p>&nbsp;</p><p><strong>Antihistamines, Phenothiazines and others:</strong></p><p>Simultaneous use of antihistamines, buclizine, cyclizine, loxapine, meclozone, phenothiazines, thioxanthenes or trimethobenzamines may mask ototoxicity symptoms (such as dizziness and tinnitus).</p><p>&nbsp;</p><p><strong>Pyroxidine + altretamine combination:</strong></p><p>During a randomised study of the treatment of advanced ovarian cancer, the response time was unfavourably affected when pyridoxine was used in combination with altretamine (hexamethylmelamine) and cisplatin.</p><p>&nbsp;</p><p><strong>Paclitaxel:</strong></p><p>Treatment with cisplatin prior to an infusion with paclitaxel may reduce the clearance of paclitaxel by 33% and therefore can intensify neurotoxicity.</p><p>&nbsp;</p><p><strong>Anti-convulsant agents:</strong></p><p>In patients receiving cisplatin and anticonvulsants, plasma levels of anticonvulsant agents (e.g. phenytoin) may be decreased and potentially become subtherapeutic. This is possibly as a result of decreased absorption and/or increased metabolism. In these patients, serum levels of anticonvulsants should be monitored and dosage adjustments made a necessary.</p><p>&nbsp;</p><p>Simultaneous use of myelosuppressives or radiation will boost the effects of cisplatin&#39;s myelosuppressive activity. The occurrence of nephrotoxicity caused by cisplatin may be intensified by concomitant treatment with antihypertensives containing furosemide, hydralazine, diazoxide, and propranolol&rdquo; and &ldquo;Cisplatin given in combination with bleomycin and vinblastin can lead to a Raynaud-phenomenon.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/ Contraception in males and females</u></p><p>&nbsp;</p><p>Women of childbearing potential should use effective contraception during treatment with cisplatin and for at least 29 weeks (at least 7 months) following the last dose. Men with female partners of childbearing potential should be advised to use effective contraception during treatment with cisplatin and for at least 17 weeks (at least 4 months) after the last dose.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>Cisplatin may be toxic to the foetus when administered to a pregnant woman.</p><p>&nbsp;</p><p>Cisplatin has been shown to be teratogenic, embryotoxic and carcinogenic in mice and rats (see section 5.3).</p><p>&nbsp;</p><p>Cisplatin should not be used during pregnancy unless the clinician considers the risk in an individual patient to be clinically justified.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Limited data from published literature report presence of cisplatin in human milk. Women should not breast-feed while undergoing treatment with cisplatin and for 4 weeks after the last dose of cisplatin.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p><em>Female</em></p><p>Based on non-clinical (see section 5.3) and clinical findings, female fertility may be compromised by treatment with cisplatin. Use of cisplatin has been associated with cumulative dose-dependent ovarian failure, premature menopause and reduced fertility.</p><p>&nbsp;</p><p><em>Male</em></p><p>Cisplatin can affect male fertility. Impairment of spermatogenesis and azoospermia have been reported (see section 4.8). Although the impairment of spermatogenesis can be reversible, males undergoing cisplatin treatment should be warned about the possible adverse effects on male fertility.</p><p>&nbsp;</p><p>Both men and women should seek advice on fertility preservation before treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on ability to drive and use machines have been performed. Nevertheless, the profile of undesirable effects (like nephrotoxicity) may influence the ability to drive vehicles and use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse events (&gt;10%) of cisplatin were haematological (leukopenia, thrombocytopenia and anaemia), gastrointestinal (anorexia, nausea, vomiting and diarrhoea), ear disorders (hearing impairment), renal disorders (renal failure, nephrotoxicity, hyperuricemia) and fever.</p><p>&nbsp;</p><p>Serious toxic effects on the kidneys, bone marrow and ears have been reported in up to about one third of patients given a single dose of cisplatin; the effects are generally dose-related and cumulative. Ototoxicity may be more severe in children. Cases of delayed-onset hearing loss have been reported in the paediatric population (see section 4.4). Delayed onset occurring months/years after administration has also been reported.</p><p>&nbsp;</p><p>Frequencies are defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &le; 1/1,000); very rare (&le; 1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table of Adverse Drug Events Reported During Clinical or Postmarketing Experience</strong></p><p><strong>(MedDRA terms)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:573px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sepsis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Infection<sup>a</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Bone marrow failure, thrombocytopenia, leukopenia, anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Coombs positive haemolytic anaemia, thrombotic microangiopathy (haemolytic uraemic syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasm benign, malignant, and unspecified</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Acute leukaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anaphylactoid<sup>b</sup> reaction</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Blood amylase increased, inappropriate antidiuretic hormone secretion</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypomagnesaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Dehydration, hypokalaemia, hypophosphataemia, hyperuricaemia, hypocalaemia, tetany</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Convulsion, neuropathy peripheral, leukoencephalopathy, reversible posterior leukoencephalopathy syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cerebrovascular accident, haemorrhagic stroke, ageusia, cerebral arteritis, Lhermitte&rsquo;s sign, myelopathy, autonomic neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vision blurred, colour blindness acquired, blindness cortical, optic neuritis, papilledema, retinal pigmentation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Ototoxicity</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Tinnitus, deafness</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arrhythmia, bradycardia, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cardiac disorder</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Venous thromboembolism</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Raynaud&rsquo;s phenomenon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vomiting, nausea, anorexia, hiccups, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatic enzymes increased, blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rash, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure acute, renal failure<sup>c</sup>, renal tubular disorder</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abnormal spermatogenesis</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site condition</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pyrexia (very common), asthenia, malaise, injection site extravasation<sup>d</sup></p></td></tr></tbody></table><p>a: Infectious complications have led to death in some patients.</p><p>b: Symptoms include facial oedema, flushing, wheezing, bronchospasm, tachycardia, and hypotension.</p><p>c: Elevations in BUN and creatinine, serum uric acid, and/or decrease in creatinine clearance are subsumed under renal insufficiency/failure.</p><p>d: Local soft tissue toxicity including cellulitis, fibrosis, and necrosis (common) pain (common), oedema (common) and erythema (common) as the result of extravasation.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>CAUTION IS ESSENTIAL IN ORDER TO PREVENT AN INADVERTANT OVERDOSE.</strong></p><p>&nbsp;</p><p>Symptoms of overdose involve above mentioned side effects in an excessive manner. Efficient hydration and osmotic diuresis can aid in reduction of toxicity, provided this is applied immediately after overdose. In case of overdose (&gt; 200 mg/m2), direct effects on the respiratory centre are possible, which might result in life threatening respiratory disorders and acid base equilibrium disturbance due to passage of the blood brain barrier.</p><p>&nbsp;</p><p>An acute overdose of cisplatin may result in renal failure, liver failure, deafness, ocular toxicity (including detachment of the retina), significant myelosuppression, untreatable nausea and vomiting and/or neuritis. An overdose may be fatal.</p><p>&nbsp;</p><p>There is no specific antidote in the event of an over dosage of cisplatin. Even if haemodialysis is initiated 4 hours after the overdose it has little effect on the elimination of cisplatin from the body following a strong and rapid fixation of cisplatin to proteins.</p><p>&nbsp;</p><p>Treatment in the event of an overdose consists of general support measures.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antineoplastic agents, Platinum compounds, ATC code: L01XA01</p><p>&nbsp;</p><p>Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent.</p><p>&nbsp;</p><p>Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radio-sensitising, and antimicrobial properties.</p><p>&nbsp;</p><p>Cisplatin does not appear to be cell cycle specific.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>There is good uptake of cisplatin by the kidneys, liver and intestine. More than 90% of platinum containing species remaining in the blood are bound (possibly irreversibly) to plasma proteins.</p><p>&nbsp;</p><p>Penetration into the CSF is poor although significant amounts of cisplatin can be detected in intracerebral tumours.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The clearance of total platinum from plasma is rapid during the first four hours after intravenous administration, but then proceeds more slowly because of covalent binding to serum proteins.&nbsp; Levels of unbound platinum fall with a half-life of 20 minutes to 1 hour depending on the rate of drug infusion.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination of intact drug and various platinum-containing biotransformation products is via the urine. About 15-25% of administered platinum is rapidly excreted in the first 2-4 hours after administration of cisplatin. This early excretion is mostly of intact cisplatin. In the first 24 hours after administration, 20-80% is excreted, the remainder representing drug bound to tissues or plasma protein.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat dose toxicity models, renal damage, bone marrow depression, gastrointestinal disorders, ototoxicity, neurotoxicity, and immunosuppression have been observed.</p><p>&nbsp;</p><p>Cisplatin is mutagenic in numerous <em>in vitro</em> and <em>in vivo</em> tests. In long term studies, it has been shown that cisplatin is carcinogenic in mice and rats.</p><p>&nbsp;</p><p>Non-clinical findings in mice showed that cisplatin caused direct damage to primordial follicle oocytes, leading to apoptosis, and ovarian depletion. Cisplatin causes testis damage and decreased sperm counts in mice, primarily through effects on differentiated spermatogonia. These findings suggest potential effects on male and female fertility.</p><p>&nbsp;</p><p>Cisplatin is embryotoxic in mice and rats, and in both species, deformities have been reported.</p><p>&nbsp;</p><p>Studies in rodents have shown that exposure during pregnancy can cause tumors in adult offspring.</p><p>&nbsp;</p><p>Other anti-neoplastic substances have been shown to be carcinogenic and this possibility should be borne in mind in long term use of cisplatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Sodium chloride</p><p>Dilute hydrochloric acid</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is a total loss of cisplatin in 30 minutes at room temperature when mixed with metoclopramide and sodium metabisulfite in concentrations equivalent to those that would be found on mixing with a commercial formulation of metoclopramide.</p><p>&nbsp;</p><p>Cisplatin and sodium bisulfite have been known to react chemically. Such antioxidants might inactivate cisplatin before administration if they are present in intravenous fluids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cisplatin must not be used after the expiry date which is stated on the vial label and carton after 'EXP'. Where only a month and year is stated, the expiry date refers to the last day of that month.

Prior to first use: 2 years.
In use: 24 hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Prior to first use</u>: Do not store above 25&deg;C. Do not refrigerate or freeze. Keep container in the outer carton in order to protect from light.</p><p>&nbsp;</p><p><u>In use:</u> Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20&ordm;C. The diluted product should not be refrigerated. From a microbiological point of view, however, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and dilution should take place in controlled and validated aseptic conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50 mg/50 ml presentations in Type I amber glass vials and Onco-Tain<sup>&reg;</sup> vials.</p><p>&nbsp;</p><p>Supplied in packs containing:</p><p>1 x 50 mg/50 ml vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single use only. Discard any unused contents.</p><p>&nbsp;</p><p>Refer to local cytotoxic handling guidelines.</p><p><strong>&nbsp;</strong></p><p><strong><u>Dilution:</u></strong></p><p><strong>&nbsp;</strong></p><p>Cisplatin 1 mg/ml sterile concentrate should be diluted in 2 litres of 0.9% sodium chloride injection.&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong><u>Administration:</u></strong></p><p><strong>&nbsp;</strong></p><p>Should be administered only by or under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents.</p><p>&nbsp;</p><p><strong><u>Preparation (Guidelines):</u></strong></p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapeutic agents should be prepared for administration only by professionals who have been trained in the safe use of the preparation.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operations such as reconstitution, dilution and transfer to syringes should be carried out only in the designated area.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The personnel carrying out these procedures should be adequately protected with clothing, gloves and eye shield.</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant personnel are advised not to handle chemotherapeutic agents</p><p>&nbsp;</p><p><strong><u>Contamination:</u></strong></p><p>&nbsp;</p><p>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of contact with the skin or eyes, the affected area should be washed with copious amounts of water or normal saline. A bland cream may be used to treat the transient stinging of skin. Medical advice should be sought if the eyes are affected.</p><p>&nbsp;</p><p>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of spillage, operators should put on gloves and mop up the spilled material with a sponge kept in the area for that purpose. Rinse the area twice with water. Put all solutions and sponges into a plastic bag and seal it.</p><p>&nbsp;</p><p><strong><u>Disposal:</u></strong></p><p>&nbsp;</p><p>Syringes, container, absorbent materials, solution and any other contaminated material should be placed in a thick plastic bag or other impervious container and incinerated.</p><p>&nbsp;</p><p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong>&nbsp;</strong></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Hospira UK Limited 
Horizon, Honey Lane
Hurley
Maidenhead 
SL6 6RJ 
United Kingdom

MANUFACTURER:
Hospira Australia Pty Ltd, 1-5, 7-23 and 25-39 Lexia Place, Mulgrave, VIC 3170, Australia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2023


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>